AIM ImmunoTech Inc (AIM) Stock Price

0.7286 ▲ +0.0486 (+7.15%)
Open: 0.70 Vol: 59.94K Day's range: 0.6702 - 0.7286 Mar 13, 16:00 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
AIM Technical Analysis
5 mins 30 mins Hourly Daily Weekly
BUY NEUTRAL NEUTRAL SELL SELL
  5 mins 30 mins Hourly Daily Weekly
MA5 0.68▲ 0.68▲ 0.68▲ 0.70▲ 0.93▼
MA10 0.68▲ 0.68▲ 0.69▲ 0.70▲ 1.07▼
MA20 0.68▲ 0.69▲ 0.69▲ 0.89▼ 1.27▼
MA50 0.69▲ 0.73▼ 0.82▼ 1.07▼ 2.12▼
MA100 0.71▼ 0.89▼ 0.91▼ 1.36▼ 1.23▼
MA200 0.86▼ 0.98▼ 1.06▼ 2.34▼ 0.92▼
  5 mins 30 mins Hourly Daily Weekly
MACD 0.002▲ 0.004▲ 0.009▲ -0.006▼ -0.035▼
RSI 58.761▲ 46.996▼ 40.388▼ 38.969▼ 34.972▼
STOCH 58.134     32.388     26.892     27.204     18.355▼
WILL %R 0.000▲ -34.783     -34.924     -78.228▼ -90.954▼
CCI 251.480▲ 51.573     19.469     -46.387     -181.040▼
Latest Filters Detected On AIM
BBANDS $AIM Bollinger Bands Expanding Set Alert
MA $AIM Price Crossed Above MA(7) Set Alert
▲ GAP $AIM Open Gap Up %2 Set Alert
AIM ImmunoTech Inc News
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million
Wednesday, March 04, 2026 06:21 AM
Each right entitled the holder to purchase one unit (“Unit”), at a subscription price of $1,000 per Unit, consisting of one share of the Company’s Series G Convertible Preferred Stock (the “Preferred ...
AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer
Monday, March 02, 2026 06:17 AM
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced an agreement with the PPD™ clinical research business of Thermo Fisher Scientific to design AIM’s anticipated Phase 3 ...
AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer
Monday, February 23, 2026 05:55 AM
OCALA, Fla., Feb. 23, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced milestones in the expected timeline for the ongoing Phase 2 clinical ...
AIM historical stock data
date open high low close volume
13/03/26 0.70 0.7286 0.6702 0.7286 59,940
12/03/26 0.691 0.72 0.6633 0.68 261,409
11/03/26 0.7149 0.722 0.675 0.6753 112,627
10/03/26 0.7254 0.7645 0.671 0.70 79,759
09/03/26 0.71 0.7399 0.6601 0.7245 98,796
06/03/26 0.663 0.78 0.6411 0.6944 327,735
05/03/26 0.699 0.7029 0.6141 0.641 266,494
04/03/26 0.7229 0.7528 0.6811 0.6908 161,415
03/03/26 0.78 0.78 0.6675 0.70 199,352
02/03/26 0.93 0.9473 0.7725 0.7725 377,678
Quote Details
52wk Low:0.063
52wk High:20.35
Vol:59.94K
Avg Vol(3m):27.7M
1Y Chng:+192.02%
1M Chng:-36.64%
Add to Watch List
More Information
Index NYSE AMEX Composite
Market Cap. 2.87M